Clinical activity of folinic acid in patients with chronic fatigue syndrome

Arzneimittelforschung. 2006;56(6):399-404. doi: 10.1055/s-0031-1296741.

Abstract

A high incidence of severe B-cell immunodeficiency and chronic reactivated Epstein-Barr virus (EBV) infection in patients with chronic fatigue syndrome (CFS) is reported herein. Of the 58 patients evaluated, 100% had evidence of prior EBV exposure and 72% had evidence for reactivated EBV infection. Notably, 94% of CFS patients had B-cell immunodeficiency with a marked depletion of their CD19+IgM+ mature B-lymphocyte population. A remarkable 81% of CFS patients experienced subjective improvement of their symptoms after treatment with folinic acid (CAS 58-05-9, leucovorin). The findings provide unprecedented evidence that CFS frequently is a folinic acid responsive clinical entity accompanied by B-cell immunodeficiency and inappropriate antibody responses to EBV.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Antibodies, Viral / biosynthesis
  • Antibodies, Viral / immunology
  • Antigens, Viral / immunology
  • B-Lymphocytes / immunology
  • Biomarkers
  • Capsid / immunology
  • Epstein-Barr Virus Infections / complications
  • Epstein-Barr Virus Infections / immunology
  • Fatigue Syndrome, Chronic / complications
  • Fatigue Syndrome, Chronic / drug therapy*
  • Female
  • Flow Cytometry
  • Humans
  • Immunologic Deficiency Syndromes / complications
  • Immunologic Deficiency Syndromes / immunology
  • Leucovorin / therapeutic use*
  • Male
  • Middle Aged
  • Pain / complications
  • Pain / drug therapy
  • Phenotype
  • Recurrence

Substances

  • Antibodies, Viral
  • Antigens, Viral
  • Biomarkers
  • Leucovorin